NCT03937635 2026-04-03
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Eastern Cooperative Oncology Group
Phase 3 Recruiting
Clinical Trials
30 trialsNCT04566328 2026-04-03
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Eastern Cooperative Oncology Group
Phase 3 Recruiting
NCT05552976 2026-04-01
SUCCESSOR-2
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT05519085 2026-03-24
SUCCESSOR-1
Celgene
Phase 3 Recruiting
NCT05730036 2026-03-06
LINKER-MM3
Regeneron Pharmaceuticals
Phase 3 Recruiting
NCT00572169 2026-02-05
UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy
University of Arkansas
Phase 3 Active not recruiting
NCT01208662 2026-01-22
DFCI 10-106
Dana-Farber Cancer Institute
Phase 3 Active not recruiting
NCT07285239 2025-12-16
PrE1005
PrECOG, LLC.
Phase 3 Not yet recruiting
NCT06022939 2025-09-15
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
SWOG Cancer Research Network
Phase 3 Recruiting
NCT01863550 2025-09-08
Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
Eastern Cooperative Oncology Group
Phase 3 Active not recruiting
NCT05561387 2025-06-04
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
SWOG Cancer Research Network
Phase 3 Recruiting
NCT03151811 2024-01-30
OCEAN
Oncopeptides AB
Phase 3 Terminated
NCT02516696 2023-06-05
BiRd vs Rd
Weill Medical College of Cornell University
Phase 3 Terminated
NCT01335399 2022-09-30
ELOQUENT - 1
Bristol-Myers Squibb
Phase 3 Completed
NCT01239797 2022-06-01
ELOQUENT - 2
Bristol-Myers Squibb
Phase 3 Completed
NCT01078454 2022-02-01
Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis
National Cancer Institute (NCI)
Phase 3 Completed
NCT01109004 2021-12-09
BMT CTN 0702
National Heart, Lung, and Blood Institute (NHLBI)
Phase 3 Completed
NCT00075829 2021-11-01
BMT CTN 0102
National Heart, Lung, and Blood Institute (NHLBI)
Phase 3 Completed
NCT00928486 2019-11-20
A Safety Confirmation Study on Lenalidomide With Dexamethasone In Japanese Patients With Previously Treated Multiple Myeloma
Celgene
Phase 3 Completed
NCT03402295 2018-01-18
GBRAM003r
Grupo de Estudos Multicentricos em Onco-Hematologia
Phase 3 Completed
NCT00083915 2017-11-20
DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE Consolidation
University of Arkansas
Phase 3 Completed
NCT00056160 2017-10-19
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Celgene
Phase 3 Completed
NCT02248428 2017-09-06
CTd
Jinling Hospital, China
Phase 3 Unknown
NCT01971658 2015-10-07
IFM2013-04
Nantes University Hospital
Phase 3 Completed
NCT00522392 2015-06-26
Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone
National Cancer Institute (NCI)
Phase 3 Terminated
NCT00002548 2015-03-06
SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma
SWOG Cancer Research Network
Phase 3 Completed
NCT00005834 2015-03-06
S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma
SWOG Cancer Research Network
Phase 3 Terminated
NCT00215943 2014-04-17
Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD)
H. Lee Moffitt Cancer Center and Research Institute
Phase 3 Terminated
NCT01296503 2011-02-15
Thalidomide Plus Dexamethasone as Maintenance Therapy for Multiple Myeloma
Grupo de Estudos Multicentricos em Onco-Hematologia
Phase 3 Completed
NCT00179647 2010-03-16
Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma
Celgene
Phase 3 Completed